Randomized, open-label, hypothesis-generating study (541 participants enrolled; 250 met final analysis criteria) evaluated two proprietary non-invasive neuromodulation technologies, electroCore’s cervical…
Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3…
WILMETTE, Ill., Nov. 12, 2026 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical…
OPHI marks another important step in CollPlant’s strategy to expand and focus its operations built around LightSolver’s all-optical Laser Processing…
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women…
Net Income was positive for the second consecutive quarter, and Adjusted EBITDA1 positive for its third consecutive quarter. Net Revenue…
– Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of…
RemeGen’s expertise and next generation engineering expand Vor Bio’s leadership in the BAFF/APRIL field RC298 is a next generation, long-acting…
Company to report third quarter 2026 financial results and host conference call at 8:30 a.m. ET HOUSTON, Nov. 12, 2026…
– Company plans to evaluate atebimetinib in combination with chemotherapy in a Phase 2 clinical trial in patients with anaplastic…
